BDX vs EBS
Becton Dickinson and Company (BDX) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. EBS currently screens at market cap $416.4M.
Not investment advice. Open the BDX and EBS stock pages for the full models.
Not investment advice.